To compare the efficacy of memantine with that of valproate as a prophylactic treatment for episodic migraine within three months. The efficacy, safety, and response rate were evaluated.
Methods:
Prospective, randomized, double-blind, controlled clinical trial randomized participants were divided into two groups. The memantine group received memantine 10 mg twice daily, and the valproate group received valproate 500 mg twice daily.
Results:
Thirty-three patients participated in the study; 27 completed the treatment protocol, 14 in the memantine group, and 13 in the valproate group. The mean number of migraine attacks per month in the memantine group was 5.31 [standard deviation (SD) ± 1.54] initially and 0.93 (SD ± 1.49) at the end of treatment, noting a decrease of 4.21 (SD ± 1.76; P < 0.001). In the valproate group, the mean number of migraine attacks per month was 5.35 (SD ± 1.11) initially and 0.77 (SD ± 1.16) at the end of treatment, with a difference of 4.5 (SD ± 1.39; P < 0.001). All 27 patients had excellent response rates. Adverse effects were infrequent and mild in severity.
Conclusions:
A clinical trial compared the efficacy of memantine with that of valproate (first-line drug) as a prophylactic treatment. A significant reduction in attacks was noted in both drugs. Memantine could be a new preventive treatment option for migraine (ClinicalTrials.gov identifier: NCT04698525).
Migraine is one of the three most debilitating diseases worldwide [1]. Its 1-year prevalence is approximately 15–18% in women and 6% in men, thus creating a sizeable socioeconomic problem [2].
Prophylactic treatment aims to decrease the frequency, duration, and severity of migraine attacks [3]. The first-line, evidence-based drugs for migraine treatment with established efficacy are sodium valproate, topiramate, propranolol, and metoprolol [4]. However, oral preventive medications showed adherence rates of 26–29% at 6 months, which diminished to 17–20% at 12 months. There are new preventive therapies for migraine, such as calcitonin gene-related peptide (CGRP) monoclonal antibodies, administered subcutaneously or intravenously on a monthly to quarterly basis. However, their cost is significantly higher than that of oral therapies, and unfortunately, public health systems in developing countries need access to them [5, 6].
One of the first evidence points to use the memantine was the role of glutamate in cortical spreading depression, an extreme depolarization of neuronal membrane that results in the release of this neurotransmitter, and a transient increase of this followed by a decrease in cerebral blood flow [7]. Levels of glutamate are also increased in the trigeminocervical complex after stimulation of dural structures. Other studies have found high levels of glutamate in the blood of patients with migraine and cerebrospinal fluid in patients with chronic migraine [8]. Memantine is a moderate-affinity uncompetitive N-methyl-D-aspartatic acid (NMDA) receptor antagonist [8, 9]. Charles et al. [10] reported a series of 71 patients with refractory migraine who received memantine as a preventive treatment for two months, 54 of whom reported a 50% reduction in headache frequency and proposed it as an excellent therapeutic possibility given the safety of memantine as a preventive treatment for refractory migraine. Noruzzadeh et al. [11] conducted, to our knowledge, the first randomized, double-blind, placebo-controlled clinical trial aimed at evaluating the efficacy of memantine as a prophylactic treatment for migraine with aura. Patients in the memantine group showed a significant reduction in the monthly frequency of attacks than those in the placebo group [11].
Our study aimed to evaluate the efficacy and safety of memantine and compare it with that of sodium valproate in the prophylactic treatment of migraine. Considering comparing a different therapeutic possibility with a standard one.
This study was conducted under the hypothesis that “the frequency of migraine attacks under prophylactic treatment with memantine is equal to or lower than that observed with sodium valproate for three months in adult patients with episodic migraine”.
Materials and methodsStudy design
Randomized, double-blind, controlled pilot trial. It was conducted at the Neurology Service, Central Hospital “Dr. Ignacio Morones Prieto” at San Luis Potosi, Mexico, from July 2019 to October 2020. The study was presented to be approved by the research and ethics committees of Hospital Central. It was also registered in the National Institutes of Health Clinical Trials of the United States (registration No. 74-19 in the HC and NCT04698525 for clinical trials).
Participants
Inclusion criteria: adults aged 18–65 years with the antecedent of episodic migraine with or without aura in the least 12 months that met the requirements specified by the International Classification of Headache Disorders, 3rd edition (beta version) [12]. Besides, patients were required to have four or more migraine attacks and less than fifteen days per month in the last three months before the study; patients were not under prophylactic treatment, and to be considered, they needed to sign an informed consent.
Participants were automatically excluded from the study if they were pregnant or lactating, had ≥ 15 headache days per month during the last three months before the study (chronic migraine), had other types of primary or secondary headaches, and had an allergy to memantine or valproate.
Procedures and interventions
Recruitment was carried out from July 2019 to August 2020 in the Neurology Service, Central Hospital “Dr. Ignacio Morones Prieto” at San Luis Potosi, Mexico. Patients who met the inclusion criteria and signed the informed consent form participated in the study.
Computer-generated numbers that perform random assignments were used to create a random assignment sequence. Patients were randomized into the memantine or valproate group. Investigators and patients were blinded, and the assignment was randomized at study entry, except for the study technician who performed the randomization.
The protocol included five clinic visits follow-up appointments Neurology Outpatient Service. The first was a screening and run-in period of 4 weeks, and patients were randomized at the second visit; each subsequent visit was performed by the investigator every four weeks until the participant completed a period of treatment of 12 weeks, being double-blinded. The memantine group started with one 10 mg memantine tablet per night for one week, followed by an increase to one 10 mg tablet morning and night with a maximum dose of 20 mg (divided into two doses). The valproate group started with one 250 mg valproate tablet per night for one week, followed by an increase to one 250 mg tablet morning and evening with a maximum dose of 500 mg. Both memantine and valproate were donated by Torrent Pharma Mexico, which remained on the sidelines of the research.
Therapeutic efficacy and response were assessed based on information recorded by the participant in the migraine diary provided, in which they recorded the frequency, intensity, duration, triggers, and clinical features of their migraine. In addition, the Migraine Disability Assessment (MIDAS) test was performed at the second and fifth visits.
Endpoints
The primary outcome was to assess the change in attack frequency and intensity from baseline to week 12, comparing the two groups (using a migraine diary). Secondary outcomes evaluated the treatment response rate in each group, defined as a ≥ 50% reduction in migraine days; before and after treatment, migraine disability was evaluated using the MIDAS test, and the intensity of migraine was assessed through the visual analog scale (VAS), besides to identify adverse effects to sodium valproate and memantine.
Statistical analysis
A descriptive statistical analysis of the variables of interest was done. Student’s t test was used for the analysis of continuous variables. The aim was to reach a number of participants (n) of 20 for each group and did the final analysis using R software for data analysis. A P ≤ 0.05 was set to avoid an error type 1. In addition, the power was set to 0.2 to avoid an error type 2. Since the study was limited to a small number of participants per treatment, the delta was estimated with this restriction.
Results
A total of 87 participants were assessed for eligibility. Thirty-three patients underwent randomization: 16 were assigned to the memantine group and 17 to the valproate group. Among them, 14 completed the protocol in the memantine group and 13 in the sodium valproate group. The consort flow diagram can be reviewed in the Figure S1.
The participants’ characteristics were similar between both groups (Table 1). The patients’ ages ranged from 18 years to 53 years (mean = 31.36 years), and 78.78% were women, and 77.86% had migraine without aura.
Baseline demographic and clinical characteristics
Characteristic
Memantine
Sodium valproate
P*
Female sex—no (%)
13 (81.25%)
13 (76.47%)
0.54
Male sex—no (%)
3 (18.75%)
4 (23.52%)
Age
31.18 ± 10.94§
31.58 ± 7.51§
0.91
A family history of migraine (%)
10 (62.5%)
9 (52.94%)
0.82
Clinical characteristicsPhotophobia—no (%)
14 (87.50%)
16 (94.12%)
0.48
Phonophobia—no (%)
16 (100%)
10 (58.82%)
0.60
Nausea—no (%)
14 (87.5%)
17 (100%)
0.23
Disability activities of daily living (%)
15 (93.75%)
16 (94.12%)
0.74
Migraine without aura (%)
13 (81.25%)
13 (76.47%)
0.54
Migraine with aura (%)
3 (18.75%)
4 (23.52%)
0.54
Fisher’s exact test; § plus-minus values are means ± standard deviation (SD)
Primary endpoint
Before treatment, the average migraine attacks in the memantine group were 5.31 (SD ± 1.54) per month and then 0.93 (SD ± 1.49) per month after 12 weeks of treatment, noting a decrease of 4.21 (SD ±1.76) migraine attacks (P < 0.001). The average migraine attacks per month in the sodium valproate group was 5.35 (SD ± 1.11) before treatment and 0.77 (SD ± 1.16) after 12 weeks of treatment, noting a decrease of 4.5 (SD ± 1.39) migraine attacks (P < 0.001) (Figure 1).
Difference between the frequency of migraine attacks pre- and post-treatment in both groups. A clear difference in both groups is observed
Secondary endpoint
A total of 4.3 (SD ± 1.93) days of migraine attacks before treatment and 0.23 (SD ± 0.44) days of migraine attacks after 12 weeks of treatment were noted in the memantine group, showing a significant reduction of 4.3 (SD ± 1.93) days of migraine attacks (P < 0.001). In the valproate group, 5.5 (SD ± 1.25) days of migraine attacks before treatment and 0.27 (SD ± 0.55) days of migraine attacks after 12 weeks of treatment were observed, showing a significant reduction of 4.88 (SD ± 1.93) days of migraine attacks (P < 0.001). The response rate to treatment was obtained for all 27 patients (Figure 2).
The average number of migraine days before and after treatment. Clearly, a difference in the days of migraine pre- and post-treatment, an average over the past 3 months and after 3 months at the start of treatment, is observed with either the memantine or valproate group
The intensity of the migraine was evaluated using the VAS pre- and post-treatment. In the memantine group, the VAS score was 8.5 (SD ± 1.36) pre-treatment and 4.28 (SD ± 3.65) post-treatment (P < 0.00014). In the valproate group, the VAS score was 8.94 (SD ± 0.87) pretreatment and 2.5 (SD ± 0.87) post-treatment (P < 0.0000012).
For the migraine disability assessed using the MIDAS test, the MIDAS mean score was 60.87 (SD ± 25.22) pre-treatment and 15.57 (SD ± 14.32) post-treatment in the memantine group (P < 0.000004). The MIDAS score was 51.92 (SD ± 22.67) pre-treatment and 10.53 (SD ± 19.97) post-treatment in the sodium valproate group (P < 0.00002) (Figure 3).
Disability measured by MIDAS before and after treatment. A difference in the MIDAS scores for migraine pre- and post-treatment, an average over the past 3 months and after 3 months at the start of treatment, can be observed in either the memantine or valproate group
Side effects
The patients presented with non-severe side effects; eight in the memantine group and seven in the sodium valproate group showed non-severe side effects (Table 2), with somnolence being the most frequent side effect in both groups.
Adverse events according to group
Adverse event
Memantine(n = 17)
Sodium valproate(n = 16)
Clinical severity CTCAE
Any adverse event
8
7
Grade 1 mild
Somnolence
4
6
Grade 1 mild
Poor concentration
2
0
Grade 1 mild
Parasomnia
0
1
Grade 1 mild
Dizziness
2
0
Grade 1 mild
CTCAE: common terminology criteria for adverse event (from US Department of Health and human services)
Discussion
The present research is an original pilot, double-blind, randomized clinical trial comparing the efficacy of memantine with first-line treatment (sodium valproate) as a prophylactic therapy for migraine. Considering that valproate is a first-line treatment in migraine prophylaxis.
Intending to recruit 40 patients because this was a pilot study, the Neurology Outpatient Clinic was suspended due to the coronavirus disease 2019 (COVID-19) pandemic. Finally, 33 patients were recruited, three lost follow-ups, and 3 abandoned the study due to COVID-19, with 27 patients completing the treatment protocol.
Compared to the study by Noruzzadeh et al. [11], in which the memantine group had a migraine frequency of 5.4 + 2.5 per month after three months of treatment, the baseline migraine frequency was 1.9. These results were similar to our study in the memantine group, with a mean number of migraine attacks of 5.31 before treatment and 0.92 after three months of treatment, with a difference of 4.39 migraine attacks (P < 0.001). Concerning the results in those taking sodium valproate, a Class 1A drug, our research observed a reduction of 4.5 migraine attacks (P < 0.001). Therefore, both drugs have oral administration in their presentation and are pretty good in acceptance; titration does not seem necessary, but taking a dose one step lower might be good looking for better tolerance. Valproate in a low dosage as used in this study had no undesired side effects such as weight gain, tremors, or alopecia. Memantine, on the other hand, offered a reduction in pain days, a lowering in intensity and duration of pain, and had lower disability effects and it is possible that memantine is safe enough that its use in pregnancy (Class B) has been proposed [13]. Both memantine and valproate have different action mechanisms, so their combined use is also possible; these can also be combined with monoclonal antibodies as a different possible therapy for refractory patients.
In conclusion, memantine can be a new prophylactic treatment option in migraine patients; it is safe, easy to administer, and effective as valproate. However, further clinical trials with a more significant number of samples are required to corroborate the findings of this study. In synthesis, migraine predominates in women. Its prevalence follows a bimodal pattern, with a peak at around 35 years of age and another at 50 years of age, affecting the productive and reproductive age population [14]. Prophylactic treatment aims to decrease migraine attacks’ frequency, duration, and severity. Memantine is a moderate-affinity uncompetitive NMDA receptor antagonist, an ionotropic glutamate receptor. Memantine could be a new prophylactic treatment option in patients with migraine. Our study showed that the efficacy and safety of memantine are comparable to those of sodium valproate, both considered excellent and safe.
AbbreviationsMIDAS
Migraine Disability Assessment
SD
standard deviation
VAS
visual analog scale
Supplementary materials
The supplementary material for this article is available at: https://www.explorationpub.com/uploads/Article/file/100442_sup_1.pdf.
DeclarationsAcknowledgments
Thanks are due to Torrent Pharmaceuticals, Mexico for providing both memantine and valproate for this study.
Author contributions
DVG: Conceptualization, Resources, Data curation, Writing—original draft, Writing—review & editing. IRL: Conceptualization, Writing—review & editing. AON: Investigation, Writing—review & editing. FRR: Resources. HGHR and JMSM: Formal analysis. All authors read and approved the submitted version.
Conflicts of interest
The authors declare that they have no conflicts of interest.
Ethical approval
The protocol study was approved by the Research and Ethics committees of Hospital Central (no. 74-19). It was also registered in the National Institutes of Health Clinical Trials of the United States (registration NCT04698525 for clinical trials) and complied with the Declaration of Helsinki and its later amendments.
Consent to participate
Informed consent to participate in the study was obtained from all participants.
Consent to publication
Informed consent to publication was obtained from relevant participants.
Availability of data and materials
The datasets for this study can be found in the Clinical Trials of the National Institutes of Health of the United States (https://clinicaltrials.gov/ct2/results?pg=1&load=cart&id=NCT04698525).
GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017Lancet2018392178985810.1016/S0140-6736(18)32279-730496104PMC6227754BilleBA 40-year follow-up of school children with migraineCephalalgia1997174889110.1046/j.1468-2982.1997.1704488.x9209767SchwedtTJPreventive therapy of migraineContinuum (Minneap Minn)20182410526510.1212/CON.000000000000019926252585PMC4640499SilbersteinSDHollandSFreitagFDodickDWArgoffCAshmanEEvidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the quality standards subcommittee of the American Academy of Neurology and the American Headache SocietyNeurology20127813374510.1212/WNL.0b013e3182535d2022529202PMC3335452HeppZDodickDWVaronSFGillardPHansenRNDevineEBAdherence to oral migraine-preventive medications among patients with chronic migraineCephalalgia2015354788810.1177/033310241454713825164920NguyenJLMunshiKPeasahSKSwartECSKohliMHendersonRet al.Trends in utilization and costs of migraine medications, 2017–2020J Headache Pain20222311110.1186/s10194-022-01476-y36031609PMC9420279DodickDWMigraineLancet201839113153010.1016/S0140-6736(18)30478-129523342ChanKMaassenVanDenBrinkAGlutamate receptor antagonists in the management of migraineDrugs20147411657610.1007/s40265-014-0262-025030431FerrariARustichelliCBaraldiCGlutamate receptor antagonists with the potential for migraine treatmentExpert Opin Investig Drugs20172613213010.1080/13543784.2017.139541129050521CharlesAFlippenCRomeroReyes MBrennanKCMemantine for prevention of migraine: a retrospective study of 60 casesJ Headache Pain200782485010.1007/s10194-007-0406-717901918PMC3451671NoruzzadehRModabberniaAAghamollaiiVGhaffarpourMHarirchianMHSalahiSet al.Memantine for prophylactic treatment of migraine without aura: a randomized double-blind placebo-controlled studyHeadache2016569510310.1111/head.1273226638119Headache classification committee of the International Headache Society (IHS) the international classification of headache disorders, 3rd editionCephalalgia201838121110.1177/033310241773820229368949WellsRETurnerDPLeeMBishopLStraussLManaging migraine during pregnancy and lactationCurr Neurol Neurosci Rep2016164010.1007/s11910-016-0634-927002079ToniniMCGender differences in migraineNeurol Sci20183977810.1007/s10072-018-3378-229904873